MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 100mg tablets (UCB Pharma Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 150mg tablets (UCB Pharma Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 200mg tablets (UCB Pharma Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 50mg tablets (UCB Pharma Ltd).

Stability Notes

There are no stability notes available for this medicine.

Provenance

This compatibility recommendation is derived from Sertraline 50mg tablets (Accord Healthcare Ltd).

Stability Notes

There are no stability notes available for this medicine.

Provenance

This compatibility recommendation is derived from Sertraline 100mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from moisture. Store in airtight containers.

Provenance

This compatibility recommendation is derived from Phenoxymethylpenicillin 250mg tablets (Kent Pharma (UK) Ltd).

Stability Notes

Store in airtight containers. Protect from light. Maxumum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Cordarone X 100 tablets (Zentiva Pharma UK Ltd).

Stability Notes

Store in airtight containers. Protect from light. Maxumum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Cordarone X 200 tablets (Zentiva Pharma UK Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arimidex 1mg tablets (AstraZeneca UK Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.